Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Global and US biotech shares have recovered from their lows on signs that the chaos created by the Trump administration is ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

While drugmakers battle over costs, MoveSmarter Health, a U.S. startup launched in Argentina, is sidestepping the fray with a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...